Mary B Todd, DO

Professor, Medicine The Cancer Institute of New Jersey (CINJ) 195 Little Albany Street, Room 2005 New Brunswick, NJ 08903 toddmb@umdnj.edu

Clinical Specialty: Genitourinary malignancies Bladder, Testicular, Kidney

Degree

• Fellowship from Yale School of Medicine
• Resident from Mt. Sinai Hospital/University of Connecticut
• Internship from U.S.P.H.S. Hospital
• Undergraduate School from University of Tulsa
• BA from Oklahoma City University
• DO from Oklahoma State University College of Osteopathic Medicine

Positions

• Associate Professor of Medicine (01/1993 - 12/2002)
  Department of Medicine
  UMDNJ-Robert Wood Johnson Medical School
• Associate Professor of Medicine (01/1991 - 12/1993)
  Department of Medicine
  Yale School of Medicine
• Deputy Director (01/1993 - 12/2004)
  Administration
  The Cancer Institute of New Jersey
• Professor of Medicine (01/2002 - Present)
  UMDNJ-Robert Wood Johnson Medical School
  The Cancer Institute of New Jersey
• Chief Operating Officer (01/2005 - Present)
  Administration
  The Cancer Institute of New Jersey

Honors

• Who's Who in Medicine & Healthcare
  University of Medicine & Dentistry of New Jersey (2009)
• The Best Doctors of America
  University of Medicine & Dentistry of New Jersey (2009)
• The Best Doctors In America
  University of Medicine & Dentistry of New Jersey (2007)
• The Best Doctors In America
  University of Medicine & Dentistry of New Jersey (2008)

Society

• American Cancer Society (2002 - 2008)
• American Association for Cancer Research (1986 - Present)
• American Society for Clinical Oncology (1986 - Present)

Publications

• Mehta, A, Stein, MN, Goodin, S, Doyle-Lindrud, S, Todd, M, DiPaola, R, Rubin, E, White, E, Jeyamohan, C, Metzger, D. A phase II trial of 13-cis retinoic acid, interferon, docetaxel, and estramustine (RITE) for the treatment of hormone refractory prostate cancer (HRPC) Proceedings, Amer Soc Clin Oncol . 2007; 25:15542.
• Chabra S, Doyle-Lindrud S, Jeyamohan C, Metzger D, Todd MB, DiPaola RS, Goodin S, Stein MN. Clinical activity of transdermal estradiol in patients with hormone and chemotherapy refractory prostate cancer. Proceedings, Amer Soc Clin Oncol Part I. 2007; 25:15619.
• Goodin,S, Medina, P, Shih, WH, Capanna, T, Abraham, S, Rao, KV, Doyle-Lindrud, S, Todd, MB, DiPaola, RS. Docetaxel in patients with PSA progression after local therapy for prostate cancer. Journal of Clinical Oncology. 20055; 15:3352-7.
• Vamos D, Kane MP, Nishioka J, Lisi S, Neceskas JR, Rubin EH, Aisner J, Shih J, Todd M, Goodin S. Evaluation of barriers to clinical trial enrollment through a novel pharmacy quality assurance tool. Proc. Am. Soc Clin Oncolo. 2007; 25:675S.

Research

• Genitourinary tumors; biological response modifiers in renal cell cancer; new therapies in transitional cell cancer; and production of coagulation factors by Leukemic cells and other malignant cells. Dr. Todd was instrumental in obtaining a voluntary agreement between all the major insurers in New Jersey to reimburse for routine patient care costs for patients enrolled in all phases of approved cancer clinical trials.